Azenta提前收回B Medical出售相关3500万美元卖方贷款，完成6300万美元现金对价回收

----- azta-20260903.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
September 3, 2026
Azenta, Inc.
(Exact name of registrant as specified in its charter)
Delaware
0-25434
04-3040660
(State or Other Jurisdiction
of Incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)
200 Summit Drive
,
Burlington
,
MA
01803
(Address of principal executive offices and Zip Code)
(
888
)
229-3682
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value
AZTA
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 7.01. Regulation FD Disclosure.
On September 4, 2026, Azenta, Inc. (the “Company”) issued a press release announcing the repayment in full of the vendor loan described in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
As previously disclosed in the Company’s Current Report on Form 8-K filed on July 8, 2026, on July 1, 2026, in connection with the completion of the sale by Azenta Germany GmbH, a wholly owned subsidiary of the Company, of the entire issued share capital of B Medical Systems S.à r.l. (“B Medical”) to Thelema S.à r.l. (“Thelema”), Azenta Germany GmbH entered into a Vendor Loan Agreement with Thelema (the “Vendor Loan Agreement”), pursuant to which Azenta Germany GmbH provided a secured term loan to Thelema in an aggregate principal amount of USD 35,000,000. The loan bore interest at a rate of 6.0% per annum, matured three months following the funding date, permitted repayment prior to maturity without penalty, and was secured by a pledge over 100% of the equity interests of B Medical granted pursuant to a Share Pledge Agreement, dated July 1, 2026 (the “Share Pledge Agreement”). USD 35,000,000 of the USD 63,000,000 purchase price for B Medical was satisfied at closing through the vendor loan.
On September 3, 2026, Thelema repaid the vendor loan in full prior to maturity, together with all accrued interest, in the aggregate amount of USD 35,373,333, satisfying all amounts then outstanding under the Vendor Loan Agreement. As a result, all obligations of Thelema under the Vendor Loan Agreement have been satisfied and discharged, the Vendor Loan Agreement has terminated in accordance with its terms, and the pledge granted under the Share Pledge Agreement has been released. Following the repayment, the Company has received the entire USD 63,000,000 purchase price for B Medical in cash.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
EXHIBIT
NUMBER
DESCRIPTION
99.1
Press Release Dated September 4, 2026
104
Cover Page Interactive Data File (embedded within Inline XBRL document).
Cautionary Note Regarding Forward-Looking Statements
The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the Company's capital allocation strategy following completion of the sale of B Medical. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the Company’s ability to execute on its strategic priorities and capital allocation plans, and the other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Although the Company’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made herein speaks only as of the date on which it is made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether because of new information, future developments or otherwise.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AZENTA, INC.
/s/ Ephraim Starr
Date: September 4, 2026
Ephraim Starr
Senior Vice President, General Counsel and Secretary

----- aztaprbmedicalloanrepaym.htm -----
EX-99.1
2
aztaprbmedicalloanrepaym.htm
EX-99.1
aztaprbmedicalloanrepaym
Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems BURLINGTON, Mass., September 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.à r.l. to Thelema S.à r.l. As part of the transaction, which closed on July 1, 2026, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, Inc., entered into a Vendor Loan Agreement with Thelema S.à r.l., pursuant to which Azenta Germany GmbH provided a secured term loan to Thelema S.à r.l. in an aggregate principal amount of $35 million. The vendor loan, which was secured by a pledge over the equity interests of B Medical Systems, has been repaid in full prior to maturity, together with all accrued interest, and the share pledge securing the loan has been released. With the repayment of the vendor loan, Azenta has now received in cash the entire $63 million purchase price for B Medical Systems. "The repayment of the vendor loan completes the divestiture of B Medical Systems," said Dr. Martin D. Madaus, Interim President and Chief Executive Officer. "Azenta has now received the entire purchase price in cash, and the credit exposure associated with the transaction has been retired, supporting our disciplined approach to capital allocation." About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding Azenta's capital allocation strategy and the use of proceeds from the sale of B Medical Systems. These forward-looking statements are based on management's current expectations and are subject to known and unknown risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially include, among others, general economic and market conditions, the Company's ability to execute its strategic initiatives and capital allocation plans, and other risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Although the Company's forward-looking statements reflect the good faith judgment of its management, they are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Forward-looking statements speak only as of the
date they are made, and, except as required by applicable law, Azenta undertakes no obligation to publicly update or revise any forward-looking statement, whether because of new information, future developments or otherwise. INVESTOR CONTACT for Azenta Life Sciences: Yvonne Perron Vice President, Financial Planning & Analysis, and Investor Relations ir@azenta.com Maria Isabel Cuartas Manager, Investor Relations ir@azenta.com